Makale Çalışmasını Görüntüleyebilmek için tıklayınız.

80.    Beksac M, Haznedar R, Tuglular T, Ozdogu H, İ.Aydogdu, N.Konuk, G.Aysucak, I.Kaygusuz, S.Karakus, E.Kaya, R.Ali, Z.Gulbas, G.Ozet, H.Goker, L.Undar. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Hematol.  2011 ;86(1):16-22.

 

 

87.    Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary

JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I,

Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011 4;118(5):1239-47.

 

88.   Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach

J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da

Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J,

Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist. 2011;16(4):388-403.

 

 

105. Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, Mazzone

C, Gottardi D, Omedè P, Zweegman S, Lahuerta JJ, Zambello R, Musto P, Magarotto

V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel AI,

Liberati AM, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A,

Miguel JS, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib,

Melphalan, Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in

elderly newly diagnosed Multiple Myeloma patients: A retrospective case-matched

study. Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print]

PubMed PMID: 24273190.

 

 

 

 

109. Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116

111. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network guidelines for the management of multiple myeloma-related complications.European Myeloma Network.Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.PMID: 26432383

114. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: Expert Rev Anticancer Ther. 2015;15(9):1121. PMID:26051506

 

115. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.PMID:26035255

116. Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A. Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.PMID: 2582429

117. Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.PMID:25621805

118. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.PMID: 25439696

119. Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015 Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22.PMID:25402977

120. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-1206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. PMID:25242045

121. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE; World Marrow Donor Association Clinical Working Group Committee. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant. 2014 Jul;49(7):880-6. doi: 10.1038/bmt.2014.67. Epub 2014 Apr 7.PMID:24710563

122. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.PMID:24497560

123. Paul G. Richardson,¹ Vânia T. M. Hungria,² Sung-Soo Yoon,³ Meral Beksac,⁴ Meletios Athanasios Dimopoulos,⁵Ashraf Elghandour,⁶ Wieslaw W. Jedrzejczak,⁷ Andreas Guenther,⁸ Thanyaphong Na Nakorn,⁹ Noppadol Siritanaratkul,¹⁰ Robert L. Schlossman,¹ Jian Hou,¹¹ Philippe Moreau,¹² Sagar Lonial,¹³ Jae Hoon Lee,¹⁴ Hermann Einsele,¹⁵ Monika Sopala,¹⁶ Bourras-Rezki Bengoudifa,¹⁶ Claudia Corrado,¹⁶ Florence Binlich,¹⁷ and Jesús F. San-Miguel¹⁸ “Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment” Received 2015 Sep 8; Accepted Blood. 2016 Feb 11; 127(6): 713–721. Prepublished online 2015 Dec 2. doi: 10.1182/blood-2015-09-665018

 

129. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I,Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators..”Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma”. N Engl J Med. 2016 Aug 25;375(8):754-66.

 

130. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A,Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J,Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. “Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial”. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.

 

131. Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ,Nguyen TS, Cronier DM, Palumbo A. “Phase 2 study of tabalumab, a human anti-B-cellactivating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma”. Br J Haematol. 2016 Dec 22. doi:10.1111/bjh.14483. [Epub ahead of print] PubMed PMID: 28005265.

 

138.   Dimopoulus MA, Lonial S, White D, Moreau P, Palumbo A, San- Miguel  J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P, “Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.” Br J Haem, 178(6):896-905, September 2017

 

139.  San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG, “Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.” Br J Haematol.179(1):66-74, October 2017

 

140.  Kumar SK, Dimopoulos MA,  Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M,  Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM, “Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.”Leukemia, 31(11):2443-2448, Novenber 2017

147. Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A  “Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiplemyeloma”.Leuk Lymphoma. ISSN: 1029-2403 2018 May 9 60:1, 163-171, DOI: 10.1080/10428194.2018.1459609

 

148. Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A, “A Comparison of the Efficacy of Immunomodulatory-free Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis” Clinical Lymphoma Myeloma and Leukemia, ISSN: 1029-2403 Volume 18, Issue 3, 08 Nov 2018, Pages 163-173.e6 doi: 10.1016/j.clml.2017.12.011

150. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, M. Mark T, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, K. Nooka A, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M,  Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV, “Daratumumab Plus Bortezomib And Dexamethasone Versus Bortezomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of CASTOR” Haematologica 20 September 2018 haematol 2018. 103:12 2079-2087 194118; Doi:10.3324/haematol.2018.194118

 

152. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Soledad Duran M, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Peceliunas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Feys C, Thoret-Bauchet F, Boccadoro M, “Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study” Clınıcal Lymphoma Myeloma & Leukemıa  October  2018 V: 18 I: 10 P: E401-E419  DOI: 10.1016/j.clml.2018.06.018

 

 

160. Richardson, PG., Oriol, A., Beksac, M., Liberati, A.M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., Miguel, JS., Sunami, K., O’Gorman,  P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M., on behalf of the OPTIMISMM trial investigators (2019) “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.” Lancet Oncol.  Jun 2019;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4.

 

161.Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min C.K., Pluta, A., Chng, W.J., Kaiser, M., Zweegman, S., Mateos, M.V., Spencer, A., Iida, S., Morgan, G.,  Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A.B., Gupta, N., Labotka, R., Rajkumar, S.V., TOURMALINE-MM3 study group (2019) “Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial” Lancet. Jan 19 2019 393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4.

 

164. Kumar, S., Durie, B., Nahi, H., Vij, R., Dimopoulos, M.A., Kastritis, E., Terpos, E., Leleu, X.,  Beksac, M., Goldschmidt, H., Hillengass, J., Su, Z., Hutton, B., Cameron, C., Khan, I., Lam, A (2019) “Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma” LEUKEMIA & LYMPHOMA JAN 2 2019 ISSN: 1029-2403 Volume: 60 Issue:1 Pages:163-71 DOI:10.1080/10428194.2018.1459609  

 

 

169. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study”. The Lancet. 2019 Nov 14. doi: 10.1016/S0140-6736(19)32556-5.

 

 

176. Landgren, O., Chari, A., Cohen, Y., Spencer, A., Voorhees, P., Estell, J., Sandhu, I., Jenner, M., Williams, C., Cavo, M., van de Donk, N., Beksac, M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P., Neff, T., Heuck, C., Qi, M., Hofmeister, C., “Daratumumab Monotherapy for Patients With Intermediate-risk or High-risk Smoldering Multiple Myeloma: A Randomized, Open-label, Multicenter, Phase 2 Study (CENTAURUS)” Leukemia, DOI: 10.1038/s41375-020-0718-z  Early Access: FEB 2020

 

177. Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M.T., Dimopoulos, M.A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., van der Velden, V.H.J.,  Zamagni, E., Palumbo, G., Patriarca, F., Montefusco, V., Galli, M., Maisnar, V., Gamberi, B., Hansson, M., Belotti, A., Pour, L., Ypma, P., Grasso, M., Croockewit, A., Ballanti, S., Offidani, M., Vincelli, I.D., Zambello, R., Liberati, A.M., Andersen, N.F., Broijl, A., Troia, R., Pascarella, A., Benevolo, G., Levin, M.D., Bos, G., Ludwig, H., Aquino, S., Morelli, A.M., Wu, K.L., Boersma, R., Hajek, R., Durian, M., Borne, P.A., Toritto, T.C., Driessen, C., Specchia, G., Waage, A., Gimsing, P., Mellqvist, U.H., Kooy, M.M., Minnema, M., Mandigers, C., Cafro, A.M., Palmas, A., Carvalho, S., Spencer, A., Boccadoro, E., Sonneveld, P.,  “Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study” Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30

 

182. Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., Arriba, F., Mateos, M.V., West, S., Spencer, A., Rajkumar, S.V., Suryanarayan, K., Czorniak, M., Teng, M., Labotka, R., Dimopoulos, M.A., “Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)” Clinical Lymphoma Myeloma and Leukemia, 2020, Volume 19, Issue 10, Page e293, https://doi.org/10.1016/j.clml.2019.09.481

 

188. Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., de la Fuente, F.D., Mateos, M.V., West, S., Spencer, A., Rajkumar, S.V., Suryanarayan, K., Czorniak, M., Li, C., Teng, Z.Y., Labotka, R., Dimopoulos, M.A., “Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma” ANNALS OF HEMATOLOGY, AUG 2020, Volume: 99 Issue: 8 Pages: 1793-1804 DOI: 10.1007/s00277-020-04149-5

 

189. Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T.M., Spicka, I., Masszi, T., Lauri, B., Levin, M.D., Bosi, A., Hungria, V.,  Cavo, M., Lee, J.J., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., Min, C.K., Chanan-Khan, A.A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J.C., Shin, H.J., Sonneveld, P., Casneuf, T., DeAngelis, T., Amin, H., Ukropec, J., Kobos, R., Mateos, M.V.,  “Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk” Journal of Hematology & Oncology,  2020 Aug 20;13(1):115. doi: 10.1186/s13045-020-00948-5.